CD161 Expression on Mucosa-Associated Invariant T Cells is Reduced in HIV-Infected Subjects Undergoing Antiretroviral Therapy Who Do Not Recover CD4+ T Cells

Por Michael L Freeman, Stephen R. Morris, Michael M. Lederman
Publicado em 2017-08-01

Decreased IL-7 responsiveness is related to oxidative stress in HIV disease.

Por Magdalina Kalinowska, Douglas A Bazdar, Michael M Lederman, Nicholas Funderburg, Scott F Sieg
Publicado em 2013-01-01

Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.

Por Philip M Grant, Lauren Komarow, Janet Andersen, Irini Sereti, Savita Pahwa, Michael M Lederman, Joseph Eron, Ian Sanne, William Powderly, Evelyn Hogg, Carol Suckow, Andrew Zolopa
Publicado em 2010-07-01

Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.

Por Nicholas T Funderburg, Adriana Andrade, Ellen S Chan, Susan L Rosenkranz, Darlene Lu, Brian Clagett, Heather A Pilch-Cooper, Benigno Rodriguez, Judith Feinberg, Eric Daar, John Mellors, Daniel Kuritzkes, Jeffrey M Jacobson, Michael M Lederman
Publicado em 2013-01-01

Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Por Maura Manion, Benigno Rodriguez, Kathleen Medvik, Gareth Hardy, Clifford V Harding, Robert T Schooley, Richard Pollard, David Asmuth, Robert Murphy, Edward Barker, Kirsten E Brady, Alan Landay, Nick Funderburg, Scott F Sieg, Michael M Lederman
Publicado em 2012-01-01

A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”?

Por Michael M. Lederman, Paula M. Cannon, Judith S. Currier, Carl H. June, Hans-Peter Kiem, Daniel R. Kuritzkes, Sharon R. Lewin, David M. Margolis, Joseph M. McCune, John W. Mellors, Timothy W. Schacker, Rafick P. Sekaly, Pablo Tebas, Bruce D. Walker, Daniel C. Douek
Publicado em 2016-08-01

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Por Rajesh T Gandhi, Lu Zheng, Ronald J Bosch, Ellen S Chan, David M Margolis, Sarah Read, Beatrice Kallungal, Sarah Palmer, Kathy Medvik, Michael M Lederman, Nadia Alatrakchi, Jeffrey M Jacobson, Ann Wiegand, Mary Kearney, John M Coffin, John W Mellors, Joseph J Eron, AIDS Clinical Trials Group A5244 team
Publicado em 2010-08-01

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy

Por Mina K. Chung, Sadashiva Karnik, Joshua Saef, Cornelia Bergmann, John Barnard, Michael M. Lederman, John Tilton, Feixiong Cheng, Clifford V. Harding, James B. Young, Neil Mehta, Scott J. Cameron, Keith R. McCrae, Alvin H. Schmaier, Jonathan D. Smith, Ankur Kalra, Surafel K. Gebreselassie, George Thomas, Edward S. Hawkins, Lars G. Svensson
Publicado em 2020-08-01

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

Por Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings
Publicado em 2014-01-01